Home > Products > Biosimilars

BioSIM anti-Human SLAMF7 Antibody (Elotuzumab Biosimilar), Research Grade

Catalog: SIM0041
Cost advantage to: SIM0041
Isotype: IgG1-kappa
Product Details Specifications Application References Related Products

Product Details

This non-therapeutic biosimilar has the same variable regions as Elotuzumab (a humanized mAb targeting CD319/SLAMF7, expressed on myeloma and normal immune cells). It activates NK cells (via SLAMF7/Fc receptors), boosts CD69/IFN-γ/granzyme B, promotes myeloma cell death (ADCC), disrupts drug resistance, reduces SLAMF7+ myeloma xenografts, and enhances anti-tumor activity with lenalidomide.
 

Specifications

Product Name BioSIM anti-Human SLAMF7 Antibody (Elotuzumab Biosimilar), Research Grade
Size 1mg/5mg
Isotype IgG1-kappa
Target SLAMF7
Other Names BMS-901608, PDL063, HuLuc63, CAS: 915296-00-3
CAS 915296-00-3
Reactivity Human
Host Species Humanized
Background This non-therapeutic biosimilar has the same variable regions as Elotuzumab (a humanized mAb targeting CD319/SLAMF7, expressed on myeloma and normal immune cells). It activates NK cells (via SLAMF7/Fc receptors), boosts CD69/IFN-γ/granzyme B, promotes myeloma cell death (ADCC), disrupts drug resistance, reduces SLAMF7+ myeloma xenografts, and enhances anti-tumor activity with lenalidomide.
Applications ELISA, FACS, Functional assay, Research in vivo
Purification Protein A/G
Storage To ensure appropriate storage, Please avoid repeated freeze thaw cycles. Keep the product at 4°C for short-term needs (1–2 weeks); Store at -20°C for up to 12 months.  For long-term storage, store at -80°C.
Shipping 2-8°C with blue ice
Concentration Lot specific, generally ≥ 5.0 mg/ml
Shelf Life 12 months from the date of receipt if stored as recommended
Formulation PBS, pH 7.4, contains no stabilizers or preservatives
Sterility 0.2 μM filtered
Endotoxin ≤ 1.0 EU/mg
Purity 99%

Application References

Related Products